Whole exome/genome studies on autism spectrum disorder (ASD) identified thousands of 15 variants, yet not a coherent and systematic disease mechanism. We conduct novel 16 integrated analyses across multiple levels on ASD exomes. These mutations do not recur 17 or replicate at variant level, but significantly and increasingly so at gene and pathway 18 level. Genetic association reveals a novel gene+pathway dual-hit model, better explaining 19 ASD risk than the well-accepted mutation burden model. 20 In multiple analyses with independent datasets, hundreds of variants or genes consistently 21 converge to several canonical pathways. Unlike the reported gene groups or networks, 22 these pathways define novel, relevant, recurrent and systematic ASD biology. At sub-23 pathway level, most variants disrupt the pathway-related gene functions, and multiple 24 interacting variants spotlight key modules, e.g. cAMP second-messenger system and 25 mGluR signaling regulation by GRK in synapses. At super-pathway level, these distinct 26 pathways are highly interconnected, and further converge to a few biology themes, i.e. 27 synaptic function, morphology and plasticity. Therefore, ASD is a not just multi-genic 28 but a multi-pathway disease. 29 30 31
Introduction
Autism spectrum disorder (ASD) covers a range of complex genetic diseases. Genome 2 wide molecular profiling is a proven strategy for complex disease studies. Indeed, 3 thousands of genomic variants or loci have been identified as potential ASD causes [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . 4 These results confirm the genetic complexity of ASD and provide valuable biological 5 insights. Yet greater challenge remains: how to turn these enormous datasets into solid 6 and systematic understanding of the disease mechanism, i.e. biologically relevant 7 molecular pathways, not just a list of associated genes, their groups or networks? In fact, 8 this is the common problem remaining for all genome wide studies or complex diseases, 9 not just ASD. 10 Recently, two whole exome studies under two consortia, the Simons Simplex Collection 11 (SSC) 10, 13 and the Autism Sequencing Consortium (ASC) 11, 14 , analyzed thousands of 12 ASD families or cases-controls producing a vast amount of genetic data. These efforts 13 identified thousands of rare mutations and firmly established their roles in ASD 15 . 14 Because these variants rarely recur, major challenges remain as to: 1) evaluate the disease 15 association of individual variants; 2) pinpoint most driver events from a huge pool of 16 passengers; 3) replicate independent studies, or 4) verify their results systematically. 17 Despite the important and inspiring discoveries, a coherent and systematic understanding 18 of autism biology has not been achieved with these enormous studies 16 . 19 To address these challenges, we devised a novel integrated analysis across multiple levels, 20 i.e. variant, gene and pathway levels. This multi-level approach has major advantages 21 over the classical one-level approach. First, it produces more informative, systematic, 22 holistic genetic understanding. Second, multiple-level/angle screenings of the same data 23 is more rigorous, reaches more robust conclusions. Third, it provides more sophisticated 24 and relevant classification and prioritization of de novo (DN) mutations and redefines 25 recurrence across different levels, which makes novel and powerful analyses possible 26 with rare events. 27 We applied this approach to both SSC 10 and ASC 11 whole exome studies, and identified 28 hundreds of potential causal mutations. We quantified and identified substantial 29 consistence both within and between studies, revealing a sequential convergence from 30 variant, gene to pathway level. We deeply dissected ASD genetic association, and built a 31 novel and more inclusive gene+pathway dual-hit model which could be generalizable to 32 CNV or GWAS data. We reconstructed novel, replicable, systematic and multiscale 33 molecular mechanisms for ASD. They provide solid and actionable molecular roadmaps 34 for the development of effective and personalized ASD diagnostics and therapeutics. 35 Note this multi-level integrated analysis is generally useful for other complex diseases, 36 problems and genomic studies. 37 3 Sequential convergence from variant, gene to pathway level 1 For multi-level analysis, we first selected ASD related DN mutations, genes and 2 pathways in probands or cases in SSC or ASC studies as described in Methods. The 3 results are listed in Table 1 and Table S4 . We applied the same selection procedure to 4 siblings in SSC for control. 5 ASD mutations from different cohorts do not replicate at variant level, but increasingly 6 do so at the gene and pathway level ( Fig. 1a ). At variant level, 0 vs 1 of the 3348 ASC-7 selected variants replicate in the 1213 SSC-selected vs 3392 SSC-considered lists (p-8 value=0.74). At gene level, 42 vs 60 of the 182 ASC-selected genes are replicated in the 9 540 SSC-selected vs 1083 SSC-considered lists (p-value=9.3×10 -4 ). At pathway level, 4 10 vs 5 of the 5 ASC-selected pathways are replicated in the 9 SSC-selected vs 199 SSC- 11 considered lists (p-value=9.7×10 -6 ). Although the background (considered) space 12 collapses across the 3 levels as expected, the overlap ratio between studies keeps 13 increasing. Therefore, ASD mutations show multi-level sequential convergence. In 14 opposite, mutations from probands and siblings in the same SSC cohort do not or rarely 15 replicate at all 3 levels, and do not converge ( Fig. 1b ). 16 Besides direct replication, pathway level analysis show extra reproducability ( Fig. 1c-d ). 17 Pathway analysis statistics (-log 10 P-val) are highly correlated between SSC and ASC 18 (R 2 =0.570), but not so (R 2 =0.030) between probands and siblings in SSC. 19 The actual replicability between studies should be even higher given that 1) the genetic 20 background is much more divergent between different cohorts than between probands 21 and siblings in the same cohort; 2) the exome-seq assay and raw data processing 22 procedures differ between the two studies. 
32
Gene and pathway level analysis show extra evidence of recurrence. As described above, 33 no variants are recurrent literally, but 240 variants come from recurrent genes in probands. 34 These gene-level recurrent variants are enriched in both the selected genes and pathways 35 ( Fig. S1c ). In selected genes, such recurrent events are 31.9 and 2.53 times enriched vs in 36 other genes and in siblings (p-vals <0.001). In selected pathways, recurrent events are 37 2.08 and 3.21 times enriched vs outside the pathways and in siblings (p-vals <0.001). For 38 4 siblings, the selected genes but not the selected pathways are enriched for recurrent 1 variants. 2 The higher-level recurrence and replication between SSC and ASC probands but not for 3 SSC siblings: 1) indicates that our multi-level approach is both sensitive and selective; 2) 4 suggests our results are likely true and general. 5 Autism genetic association dissected across multiple levels 6 In this and following sections, we work with the SSC data only unless noted otherwise. 7 The study is well controlled with simple data structure 10 , ideal for association and 8 function analysis. For association analysis, we use all DN variants for testing power. For 9 pathway and function analysis, we focus on validated variants only (Methods). 10 With no recurrence or annotation, the DN events tell little on ASD genetics at variant 11 level alone. To fully dissect the ASD genetic association, we take their gene level and 12 pathway level effects into account. Indeed, variant effects at these two levels largely 13 determine its association with ASD: 1) whether (and how much) the variant disrupts 14 genes; 2) whether (and potentially how much) it hits the selected pathways. 15 16 Probands have more variants in general, particularly those disrupt genes and hit selected 17 pathways. Probands have 55% more LGD or Likely Gene Disrupting (0.175 vs 0.113, 18 p=2.1×10 -6 ) and 11% more missense variants (0.667 vs 0.601, p=2.2×10 -2 ) than siblings, 19 but only 6% more silent variants (0.515 vs 0.484, p=7.8×10 -2 ) ( Fig. S2 row 1 ). This is 20 consistent with the original analysis 10 . In addition, they have 39% more variants within 21 selected pathways, but only 12% more outside ( Fig. 2 row 1 ). In other words, most of the 22 differences between probands and siblings fall in LGD and missense categories within 23 selected pathways. This difference is well exhibited by variant distributions in Wnt and 24 synapse pathways ( Fig. S5-7 ). 25 Proband variants are more (likely, frequently) gene disrupting. As described above, 26 probands have more events in LGD and missense categories and in general. After (Fig. 4a ). In addition, more missense variants in selected pathways 35 hit a functional domain in probands vs siblings (0.747 vs 0.558, p-val<0.05) ( Fig. 4b ), 36 5 especially in Wnt and synapse pathways ( Fig. S8-9 , and more details in Supplementary 1 Text Section 4). 2 Proband variants are more (likely, frequently) pathway hitting. Probands have higher 3 absolute event rates than siblings in selected pathways (0.11 vs 0.08, p= 4.2×10 -4 ), 4 especially in LGD (0.021 vs 0.008, p= 2.7×10 -4 ) and missense (0.053 vs 0.036, p= 5 3.5×10 -3 ) categories, but not the silent category (0.033 vs 0.032, p=0.45). After adjusted 6 for event numbers within each category or in total, probands still have consistently higher 7 pathway event rates than siblings for both LGD (0.12 vs 0.07, p= 4.1×10 -2 ) and missense 8 categories (0.08 vs 0.06, p= 2.2×10 -2 ), but not for the silent category (0.06 vs 0.07, p= 9 0.60) (row 3 in Fig. 2 ). 10 11 We proposed a gene+pathway dual-hit (or two-factor) model for ASD genetic association 12 based on our results above ( Fig. 2 column 3 ): disrupting effect on target genes (G) and 13 hitting the relevant pathways or not (P). These two factors have significant association 14 with ASD both marginally and conditionally as described above. In our model, variant 15 load/burden per person (V) becomes less relevant and marked as hidden. Because the 16 extra variants mostly fall into the gene disrupting and pathway hitting categories (Fig. 2 17 row 1, described above). 18 There is also significant interaction between gene and pathway factors ( Fig. 2 row 1) . 19 Probands and siblings have the biggest differences in variants that are both gene 20 disrupting and pathway hitting. The differences diminish outside the pathways or 21 disappear completely in the silent category. Indeed, this interaction is significant, as 22 indicated by significant overrepresentation in LGD hitting the pathways in probands (52 23 occurred vs 34.6 expected events, p=0.001, Table S1 ). 24 What we proposed is essentially a Noisy-AND model, i.e. risk genetic variant tend to be 25 both gene disrupting AND pathway hitting. The model is Noisy because our knowledge 26 on gene disrupting and pathway assignment is incomplete or penetrance incomplete.
28
We also estimate the prevalence of DN events with different gene and pathway level 29 effects ( Fig. S3 ). These statistics are similar to per patient variant burden stats ( Fig. 2 row 30 1) and consistent with our two-factor genetic model for ASD ( Fig. 2 row 1 ). With the DN 31 variants alone, this model explains at least 5% (2.8% within and 2.2% outside selected 32 pathways) of all ASD cases ( Fig. S3 ). Although consistent with the LoF mutation 33 contribution in the ASC study 11 , this is likely a substantial under-estimation, since not all 34 variants are called and not all genes in the relevant pathways are known. In addition, 35 when other types of variants (CNV, common variants or transmitted/inherited variants) 36 are considered, this model can be generic and more descriptive (more in Supplementary   37 Text Section 2). 1 Selected by our special pathway-level testing procedure, these pathways form a novel, 2 coherent yet non-redundant set of ASD disease mechanisms (Table 1) . These pathways 3 are novel in multiple aspects: 1) first time report the target pathway is involved in ASD 4 (Actin, MAPK, T-junction), 2) there are some evidence in literature, but this is the first 5 report based on whole exome/genome analysis with statistical significance (Lysine, 6 GABA, Wnt, Circ, Glut); 3) for all pathways, this is the first report with pathway graphs 7 on detailed molecular mechanisms for ASD; 4) mostly being causal, they may also 8 explain associated symptoms of ASD, including intellectual disability 18 (Glut, GABA), 9 sleeping 19 (Circ) and digestive 20 (digestion) problems. 10 Importantly, the pathway graphs integrate disease variants and genes from multiple 11 datasets: SSC 10 , ASC 11 or SFARI Gene database 21 (Fig. 4, Fig. S4 ). These pathways are 12 likely true and primary molecular mechanism for ASD as they are consistently selected in 13 these independent analyses. These analyses agree in details too: they frequently converge 14 to the same genes, gene groups (nodes) or the same signaling branch in a pathway. They 15 also complement each other. For instance, SSC and ASC data provide numerous novel 16 ASD associated genes besides those collected in SFARI Gene. 17 18 The pathway list and data integrated pathway graphs provide abundant novel, coherent 19 and systematic insights on ASD mechanism. We focus on three pathways for example. GABA transporters (GATs) on the presynaptic terminal or neighboring glial cells. 37 2) Glial cells besides the presynaptic and postsynaptic neurons. 3. The whole Glutamatergic synapse pathway is involved in ASD, particularly the 2 following parts ( Fig. 4c ): 3 1) ionotropic glutamate receptor (iGluRs, NMDARs) signal, and the postsynaptic density 4 scaffold proteins (SHANKs etc), the consequent synapse formation and plasticity. 5 2) metabotropic glutamate receptors (mGluRs, mGluR1, 5, 7, 8), the coupled G proteins 6 (Gs, Gi and Go) and the second messenger systems downstream (Ca2+, cAMP, DAG, 7 IP3). 8 3) the inhibitory autoreceptor mechanism that suppresses excess glutamate release in 9 presynaptic neurons (mGluR7, Gi/o, GRK, AC). 10 4) Glial cells besides the presynaptic and postsynaptic neurons, especially in the 11 clearance and recycle of glutamate. 12 13 Other pathways and graphs are equally informative, many of them are also supported by 14 literature (Table 1) . For details, please check the Supplementary Text Section 3 and Fig.   15 S4. 16 Subpathway biology, coherent fine details 17 We analyzed the functional consequences of DN variants in selected pathways. Here we 18 focus on missense but not LGD variants. Because the latter are highly destructive on 19 overall protein structure and function (position insensitive), while the former are subtle 20 and precisely tell what functions are perturbed in ASD (position sensitive). 21 In probands, missense variants hit the relevant functions or domains in selected pathways. 22 In Wnt signaling pathway, missense hit the histone acetylation domain KAT11 twice in 23 CREBBP (CBP) gene and TIP49 domain in RUVBL1, the scaffolding domain WD40 in 24 TBL1XR1, and the CTNNB1 binding domain in TCF7L1 (Fig. S8 ). In synapse pathways, 25 the most essential players, i.e. neurotransmitter receptors, transporters and ion channels 26 on cell membrane, are heavily targeted ( Fig. 4c-d, Fig. S6-7) . Missense variants hit the 27 neurotransmitter glutamate binding domain in GRIN2B (NMDAR) gene, the 7 28 transmembrane region of GRM7 (mGluR7), and the ion-channel domains in GABRA1 29 and CACNA1C, the Sodium:neurotransmitter symporter domain in SLC6A1 (GAT) and 30 SLC6A13 (GAT2/3), among others. 31 In opposite, missense variants in siblings often hit the non-functional regions or the less 32 relevant regions or genes ( Fig. S8-10 ).This probands-sibling difference is significant 33 overall ( Fig. 4b) and extremely so in the example pathways ( Fig. S8-9 and 34 Supplementary Text Section 4). 35 Autistic missense events on the same genes tend to hit residues extremely close and in the 36 same domain. This occurs to all cases we observed in Wnt and synapse pathways ( Fig. S8-9 : ADCY5, CREBBP, SLC6A1 and SLC6A13). These data strongly 1 suggest that missense events do not occurred in random, but precisely and consistently 2 targeting specific risky loci for ASD (p= 0.002-0.03, Supplementary Text Section 4). 3 4 We identified subpathway clusters of missense events in probands. Each event cluster 5 hits multiple interacting genes along the pathway. They reveal novel and critical 6 molecular modules in ASD biology. 7 One cluster hit the cAMP second-messenger system 22 in the Glutamatergic synapse 8 pathway ( Fig. 4d, Fig. S7 ). Two types of G proteins bind and control Adenylate cyclase 9 (AC), Gs activates while Gi/o (Gi/Go) inhibits it (green dashed box in Fig. S7 ). As shown 10 in Fig. 4d , the G-alpha domains of GNAS (Gs) and GNAO1 (Gi/o) are similar and align 11 seamlessly in 3D 23 . They compete to bind to AC C2A domain the same way. Missense 12 variants in these two genes both hit the G-alpha domain, which affect their binding to AC 13 hence AC's catalytic activity on cAMP production and downstream signal. In parallel, 14 the two missense events on AC (ADCY5) hit its C1A domain, which perturb AC's 15 catalytic function too (Fig. 4d ). In the direct upstream ( Fig. S7 ), GRM5 (mGluR5) was 16 hit by a destructive in frame deletion (K679) ( Table S5 ). GRM7 (mGluR7) was hit by a 17 missense at the 7 transmembrane region (Fig. 4c ), which likely render it a strong 18 antagonist of the transmembrane signal as an unbounded cytosol form. 19 In another cluster, GRK inhibits mGluR signaling by sequestering heterotrimeric G 20 proteins. See Supplementary Text Section 4 and Fig. S11 for details. 21 All these subpathway level biological stories we present above reveals coherent fine 22 details on ASD mechanism. This is consistent with yet complement to the integrated 23 pathway graphs ( Fig. 3 and Fig. S6-7) . 24 Superpathway biology, emergent big picture 25 The selected pathways are distinct yet highly interconnected. For example, MAPK feed 26 into canonical Wnt pathway and inhibit TCF/LEF dependent transcription ( Fig. 3a and 27 Fig. S4c ). In addition, they also share numerous other connections. For example, Wnt and 28 MAPK are both involved in adherens junctions and focal adhesion ( Fig. S4g-4h ). These 29 commonly connected pathways are also perturbed in ASD except marginally significant 30 (p.val=0.01-0.10, Table S2 ). hardware, while module II concerns synaptic transmission or the software. These 1 modules are distinct in topology too. Connections are dense within each module but none 2 between them. MAPK pathway is the only bridge node and highly connected in both 3 modules. There is 1 less prominent theme: transcription (not shown in Fig. 5 ). Both Wnt 4 and MAPK pathways end at target gene transcription, which involves chromatin 5 modification, especially histone lysine methylation branch of Lysine degradation (Table   6 1). We also did a parallel GO term analysis, which converges to the same set of 7 biological themes (Supplementary text section 5 and Fig. S12 ). 8 All mutated pathways or functions converge to synapse biology. Either synaptic function, 9 morphology or plasticity (as indicated by transcription 24,25 ) is disrupted in these cases. 10 Therefore, ASD is a multi-pathway disease not just multi-genic, and ultimately a synapse 11 disease. 12 
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Pathways of DN events, integrated molecular mechanism
Discussion
13
We conduct an integrated analysis on ASD exome mutations across multiple levels. 14 These isolated and rarely occurred events are actually connected and recurrent at higher 15 (gene and pathway) levels (Fig. 1) . In the meantime, the otherwise random and divergent 16 results become reproducible between independent studies. This cross-validation not only 17 confirms our results but also justifies our multi-level analysis approach. This novel 18 approach is equally applicable to other complex diseases.
20
We also did a multi-level association analysis, and proposed a gene+pathway dual-hit 21 model for ASD risk (Fig. 2) . The disease variants need to both: 1) disrupt the target genes; 22 and 2) hit the relevant pathways. Variants missing either factor become no or less risky, 23 including the silent variants in the selected pathways or variants outside the pathways. In We reconstruct a set of coherent and systematic molecular mechanisms for ASD ( Fig. 3-5 , 30 Table 1 ). Importantly, we discover whole pathways or molecular systems that cause the 31 disease, as supported by multiple independent datasets. These disease pathways not just 32 present a catalog of ASD genetic associations (Table S5 ), but further connect hundreds of 33 interacting genes and variants into a whole, dynamic multiscale system ( Fig. 3-5 ). They 34 reveal concrete biological mechanism, much more definitive and informative than gene The exome-seq DN variants from the SSC cohort 10 and ASC cohort 11 were used for this 3 study. Please see the original publications for details of the experimental design, quality 4 control and raw data processing. The final SSC data include 2,517 families, with 2,508 5 affected children, 1,911 unaffected siblings and the parents of each family. The ASC 6 data we used consists two cohorts: one includes1,445 trios, another includes1601cases 7 and 5397 ancestry-matched controls. The ASC paper originally included 825 trios from 8 the SSC cohort. This overlap was intentionally excluded to create two completely 9 independent datasets for downstream analysis and comparison. 10 Variant level analysis 11 Variants were divided into 3 major categories based on their effects on the target genes. 12 Silent group includes all synonymous variants and those fall in the 3'UTR, 5'UTR, 13 intergenic, intron, and non-coding regions; Missense group include missense variants; 14 LGD (likely gene disrupting) or LoF (lose of function) group includes exon indels (both 15 frame-shift and no-frame-shift), nonsense, and splice-site variants. Variants are selected 16 for gene and pathway level analyses based on a few criteria:1) LGD (or LoF) and 17 missense only, as silent variants are usually not damaging, and have little disease 18 association as a group (Fig. 2) ; 2) For SSC study 10 , we only consider validated variants, 19 which included those experimentally verified or cross-validated or called in at least 2 of 20 the 3 laboratories (CSHL, Yale or UW). 3) For ASC study 11 , we only consider DN 21 variants in the trio families or those from the case-control cohorts. 22 Gene level analysis 23 Selected variants are mapped to target genes. We select genes using the following scoring 24 function which essentially sums up the weighted evidence for each gene. Due to different study designs and data quality, we used slightly different criteria for the 29 two cohorts. In SSC, we take w j =1/n j ( number of selected variants occurred to patient i) 30 and s 0 =0.5, while in ASC w j =1 and s 0 =2. 31 Pathway level analysis 1 We selected pathways enriched for the selected genes. We test for both marginal and 2 conditional overrepresentation given the previously selected pathways. This procedure 3 ensures that pathways selected are drivers instead of passengers, which share genes with 4 the former. 5 6 The analysis is an application of the set theory. missense) groups, as described above. At pathway level, they either belong to the 1 Selected pathways or Others. 2 The ASD association of these variant groups can be measured by rate difference (over 3 noise), rate ratio (θ) or log θ between probands and siblings. To test the rate difference 4 between probands and siblings, we conducted two proportion z-test for conditional rates, 5 and two sample t-test for marginal rates. Odd ratio tests gave similar results as in our 6 conditional rate tests, but is not suitable for marginal tests on absolute variant rates. 7 Pathway data integration and visualization 8 Pathview package 26 was used for pathway based data integration and visualization. 9 Variants were first mapped to the target genes, which are then mapped and visualized 10 onto the selected KEGG pathway graphs. In disease gene view (Fig. 3, Fig. S4 ), variant 11 targeted genes from SSC and ASC, and SFARI genes are collected, integrated and shown 12 in the relevant pathways. Different data sources were marked by colors, gene level scores 13 by brightness, and corresponding pathway analysis p-values are also shown. In variant 14 type views ( Fig. S5-7) , DN variants from SSC are project and visualized on the target 15 pathways. Variant types or effects (LGD, missense, or silent) are marked by different 16 colors, their corresponding event counts are also shown. 17 Protein structure and function analysis 18 Exome variants were mapped to amino acid changes in the target protein using 19 Bioconductor VariantAnnotation package 27 Table S4 for full lists of selected variants and genes.
Figure 1 Multi-level comparison of DN mutations between or within ASD whole exome studies.
Venn diagrams and test statistics on overlap a) between SSC and ASC ASD cohorts, and b) between probands and siblings of SSC, at different levels. Correlation of pathway analysis statistics c) between SSC and ASC ASD cohorts, and d) between probands and siblings of SSC. Term "considered" or "selected" refers to items before or after selection process at each level (Methods). See Table S4 for full lists of selected variants and genes used in the analysis. genes from SFARI Gene Database. Gene level scores (Methods) are marked by color. P-values are from pathway analysis (Table 1 ). Data are integrated and visualized on KEGG pathway graphs using Pathview (23). Figure S6-7) ; d) 1 and 3D protein structures and missense variants hitting the Adenylate cyclase (AC), i.e. ADCY5, and interacting G proteins, GNAS (Gs) and GNAO1 (Gi/o). The pathway context is shown in the green dashed box in in Supplementary Fig. 7 . AC controls the production of cAMP second-messenger in synapse (Supplementary Text Section 4). Error bars represent standard error of the mean (SEM). 
